InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- PHARMAXIS ANNOUNCES IMPROVED PBS LISTING OF BRONCHITOL 18 Jul 2013 9:24AM $0.170 $0.027 fallen by 84.12%
- Appendix 4C - quarterly 17 Jul 2013 5:19PM $0.185 $0.027 fallen by 85.41%
- Pharmaxis Awarded Two ARC Linkage Grants 5 Jul 2013 9:05AM $0.145 $0.027 fallen by 81.38%
- European CF Clinical Trial in Paediatric Patients Begins 20 Jun 2013 12:41PM $0.150 $0.027 fallen by 82%
- Pharmaxis Presents New Analyses of Pooled CF Data at EU Meet 18 Jun 2013 8:31AM $0.155 $0.027 fallen by 82.58%
- Aridol FDA Import Restrictions 3 Jun 2013 9:54AM $0.140 $0.027 fallen by 80.71%
- Outcome of Business Review 28 May 2013 8:42AM $0.200 $0.027 fallen by 86.50%
- Pharmaxis Appoints Bronchitol Distributor for Poland 22 May 2013 8:35AM $0.170 $0.027 fallen by 84.12%
- FDA Meeting, Business Review Announcement End of May 14 May 2013 11:31AM $0.155 $0.027 fallen by 82.58%
- PHASE 3 CLINICAL TRIAL IN BRONCHIECTASIS (B305) 24 Apr 2013 8:57AM $0.150 $0.027 fallen by 82%
- Trading Halt 22 Apr 2013 9:04AM $0.315 $0.027 fallen by 91.43%
- Appendix 4C - quarterly 10 Apr 2013 4:56PM $0.335 $0.027 fallen by 91.94%
- PHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDA 19 Mar 2013 12:04PM $0.460 $0.027 fallen by 94.13%
- Trading Halt 19 Mar 2013 9:11AM $0.460 $0.027 fallen by 94.13%
- Pharmaxis Appoints Gary Phillips New Chief Executive Officer 12 Mar 2013 11:00AM $0.545 $0.027 fallen by 95.05%
- Bronchiectasis Phase 3 Trial Milestone 8 Mar 2013 8:57AM $0.530 $0.027 fallen by 94.91%
- Half Year Report and Accounts 15 Feb 2013 8:36AM $0.625 $0.027 fallen by 95.68%
- Pharmaxis Announces US$40 million Financing Areement 31 Jan 2013 9:16AM $0.680 $0.027 fallen by 96.03%
- Pharmaxis Receives Negative Recommendation from PADAC 31 Jan 2013 8:50AM $0.680 $0.027 fallen by 96.03%
- Trading Halt 29 Jan 2013 9:05AM $1.250 $0.027 fallen by 97.84%
- Appendix 4C - quarterly 23 Jan 2013 4:33PM $1.265 $0.027 fallen by 97.87%
- IMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UK 26 Oct 2012 11:10AM $1.320 $0.027 fallen by 97.95%
- Trading Halt 26 Oct 2012 9:42AM $1.320 $0.027 fallen by 97.95%
- Appendix 4C - quarterly 10 Oct 2012 4:27PM $1.390 $0.027 fallen by 98.06%
- Response to ASX Price Query 8 Oct 2012 3:51PM $1.265 $0.027 fallen by 97.87%

626 - 650 of 836 results

Page 26 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.